Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... Mr. Goldberg said, is Alequel™, an individualized therapy for treatment of Crohn's disease, and Optiquel™, an oral, novel peptide for autoimmune uveitis, currently involved ...
2009 NOV 23 ... used in other disease states, such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. Long-term safety data are available from the treatment of these diseases. Both ...
2009 NOV 23 ... becomes inflamed and damaged and can result in painful sores. Ulcerative colitis and Crohn's disease are the two major types of Inflammatory Bowel Disease (IBD). It is not yet known what ...
2009 NOV 23 ... expression of CEACAM6 is observed at the apical surface of the ileal epithelium in Crohn's disease (CD) patients, and CD ileal lesions are colonized by pathogenic adherent-invasive ...
2009 NOV 23 ... whether human genetic polymorphisms in the CD39 gene might influence susceptibility to Crohn's disease. We induced colitis in mice using Dextran Sodium Sulfate (DSS). Readouts included ...
2009 NOV 23 ... According to a study from the United States, "Chronic granulomatous disease (CGD), an immunodeficiency with recurrent pyogenic infections and granulomatous ...
2009 NOV 16 ... "Two natalizumab phase III studies were evaluated: the Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) study evaluated the HRQoL of CD patients during 12 weeks ...
2009 NOV 16 ... research from Bradford, the United Kingdom, "Inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) is a chronic inflammatory gastrointestinal autoimmune ...
2009 NOV 16 ... "Some of the remarkable advances being made using current genetic approaches in Crohn's disease, coronary artery disease and atrial fibrillation are described, together with examples ...
2009 NOV 23 ... TLR2, suggesting a positive relationship between these B cell inflammatory mediators and disease pathogenesis. In contrast, B cells from UC patients express TLR2 but generally do not ...
2009 NOV 16 ... "Western studies show that up to 65 per cent of patients with Crohn's disease have low serum 25-hydroxy vitamin D concentrations, and 45 per cent of these patients ...
2009 NOV 16 ... to a study from Canada, "Therapy with adalimumab has been shown to be effective in Crohn's disease (CD) patients who have lost response or are intolerant to infliximab. To determine the ...
2009 NOV 23 ... population-based rates of treatment. Overall rates of hospitalization for patients with Crohn's disease and ulcerative colitis increased significantly between 1998 and 2005 (5.1%/year and ...
2009 NOV 16 ... suggest that immunomodulators (IMs) be given prior to infliximab (IFX) in patients with Crohn's disease (CD). The package insert for IFX recommends that maintenance therapy be prescribed for ...
2009 NOV 16 ... neuropathy. Assays of autonomic function suggest that ulcerative colitis and Crohn's disease, the two major forms of IBD, have contrasting effects on sympathetic neural activity. 4. ...
2009 NOV 16 ... to recent research published in the journal Inflammatory Bowel Diseases, "Recurrence of Crohn's disease (CD) after ileal or colonic resection is common. Myenteric plexitis in the proximal ...
